On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Ty Roush is a breaking news reporter based in New York City. Eli Lilly on Monday lowered the cost of Zepbound after the pharmaceutical giant and Ozempic maker Novo Nordisk announced a deal with the ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. Starting Dec. 1, cash-paying patients ...

Eli Lilly said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of small molecule drugs, including its closely watched ...

Eli Lilly is releasing new Phase 3 trial results Tuesday. Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 ...

Nov. 21 (UPI) --Healthcare giant Eli Lilly on Friday became the first global healthcare company to hit $1 trillion in value. The Indiana-based company hit the $1 trillion market capitalization ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...